Fig. 6.

PKCζ facilitates lymphangiogenesis and lymphatic vessel remodeling in mouse xenografts. a Representative images of lymphatic vessels in tumors developed from WT and 26A cells immunohistochemically stained for LYVE-1. Scale bar, 50 μm. b The number of lymphatic vessels in the images was quantified, given as means ± S.E.M. for 8 samples (8 images) in the WT group and 10 samples (10 images) in the 26A group, *p ≤ 0.05, Mann–Whitney non-parametric test. c Analysis of the enlarged lymphatic vessel by quantifying the area of each lymphatic vessel. Values are given as means ± S.E.M. for WT (8 images) and 26A(10 images), *p ≤ 0.05, Mann–Whitney non-parametric test. d Representative images of lymphatic vessels in tumors developed from PC3 cells stably transfected with control shRNA, cop GFP control, or PKCζ shRNA lentiviral particles, immunofluorescence staining (upper panel) immunohistochemistry staining (lower panel) and for LYVE-1. Scale bar, 50 μm. e The number of lymphatic vessels in the images was quantified, given as means ± S.E.M. from control shRNA (10 images), cop GFP control (9 images), and PKCζ shRNA group (10 images), *p ≤ 0.05, Mann–Whitney non-parametric test. f Analysis of the enlarged lymphatic vessel by quantifying the area of each lymphatic vessel. Values are given as means ± S.E.M. from control shRNA (10 images), cop GFP control (9 images), and PKCζ shRNA group (10 images), *p ≤ 0.05, students’ t tests. LYVE-1 and GFP antibodies were used at 1:200 dilution